Since UM-164 is a highly effective Src and p38 MAPK inhibitor, we examined the changes in the phosphorylation levels of p38 and Src in glioma cells in response to UM-164, and the Src inhibitor Dasatinib was included as a control [40,41]. The gene discussed is SRC; the disease is glioma.